• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BCR-ABL酪氨酸激酶抑制剂CGP 57148对费城染色体阳性慢性髓性白血病细胞凋亡的选择性诱导作用

Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148.

作者信息

Dan S, Naito M, Tsuruo T

机构信息

Institute of Molecular and Cellular Biosciences, The University of Tokyo, Tokyo.

出版信息

Cell Death Differ. 1998 Aug;5(8):710-5. doi: 10.1038/sj.cdd.4400400.

DOI:10.1038/sj.cdd.4400400
PMID:10200527
Abstract

The BCR - ABL tyrosine kinase has been implicated as the cause of Philadelphia chromosome (Ph1)-positive leukemias. We report herein that CGP 57148, a selective inhibitor of the ABL tyrosine kinase, caused apoptosis specifically in bcr - abl-positive chronic myelogenous leukemia (CML) cells, K562 and KYO-1. Upon treatment with CGP 57148, CRKL, a specific substrate for BCR - ABL that propagates signals via phosphatidylinositol-3' kinase (PI3K), was dephosphorylated, indicating inhibition of BCR - ABL tyrosine kinase at the cellular level. Likewise, MAPK/ERK, a downstream mediator of Ras, was also dephosphorylated. Caspase activation and cleavage of retinoblastoma protein (pRB) accompanied the development of CGP 57148-induced apoptosis. Inhibition of caspase suppressed apoptosis and the cleavage of pRB, and in turn arrested cells in the G1 phase. These results indicate that CGP 57148 shows apoptogenic and anti-proliferative effects on bcr - abl-positive cells by blocking BCR - ABL-initiated signaling pathways.

摘要

BCR-ABL酪氨酸激酶被认为是费城染色体(Ph1)阳性白血病的病因。我们在此报告,ABL酪氨酸激酶的选择性抑制剂CGP 57148可特异性地诱导bcr-abl阳性慢性粒细胞白血病(CML)细胞K562和KYO-1发生凋亡。用CGP 57148处理后,作为BCR-ABL特异性底物并通过磷脂酰肌醇-3'激酶(PI3K)传递信号的CRKL发生去磷酸化,表明在细胞水平上BCR-ABL酪氨酸激酶受到抑制。同样,Ras的下游介质MAPK/ERK也发生了去磷酸化。半胱天冬酶激活和视网膜母细胞瘤蛋白(pRB)的裂解伴随着CGP 57148诱导的凋亡的发生。抑制半胱天冬酶可抑制凋亡和pRB的裂解,进而使细胞停滞在G1期。这些结果表明,CGP 57148通过阻断BCR-ABL启动的信号通路,对bcr-abl阳性细胞显示出凋亡诱导和抗增殖作用。

相似文献

1
Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148.BCR-ABL酪氨酸激酶抑制剂CGP 57148对费城染色体阳性慢性髓性白血病细胞凋亡的选择性诱导作用
Cell Death Differ. 1998 Aug;5(8):710-5. doi: 10.1038/sj.cdd.4400400.
2
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).酪氨酸激酶抑制剂(CGP-57148)对表达分子量为190,000的BCR-ABL蛋白的急性淋巴细胞白血病细胞中细胞增殖和BCR-ABL磷酸化的选择性抑制作用
Clin Cancer Res. 1998 Jul;4(7):1661-72.
3
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.索拉非尼通过抑制其激酶活性以激活内源性线粒体途径,从而特异性地诱导表达BCR/ABL的细胞发生凋亡。
Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14.
4
Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.选择性吡咯并嘧啶抑制剂揭示了Src家族激酶在Bcr-Abl信号转导和肿瘤发生中的必要作用。
Oncogene. 2002 Nov 21;21(53):8075-88. doi: 10.1038/sj.onc.1206008.
5
Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.抑制磷酸酪氨酸磷酸酶1B会使BCR-ABL阳性白血病细胞对ABL激酶抑制剂STI571产生抗性。
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2025-31. doi: 10.1158/1078-0432.CCR-04-2392.
6
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.抑制ABL激酶活性可阻断BCR/ABL+白血病细胞的增殖并诱导细胞凋亡。
Blood Cells Mol Dis. 1997 Dec;23(3):380-94. doi: 10.1006/bcmd.1997.0155.
7
Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.人K562和CCRF-CEM白血病细胞中DNA损伤、细胞周期及细胞凋亡的比较研究:BCR/ABL在治疗耐药中的作用
Comp Biochem Physiol C Toxicol Pharmacol. 2006 Sep;144(1):85-92. doi: 10.1016/j.cbpc.2006.06.010. Epub 2006 Jun 29.
8
Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity.Bcr-Abl介导的对细胞凋亡的抗性与持续的酪氨酸激酶活性无关。
Cell Death Differ. 2003 May;10(5):592-8. doi: 10.1038/sj.cdd.4401210.
9
Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.黄酮哌啶醇增强STI571诱导的BCR-ABL阳性人白血病细胞的线粒体损伤和凋亡。
Clin Cancer Res. 2002 Sep;8(9):2976-84.
10
Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.Bcr-Abl抑制剂在慢性粒细胞白血病细胞系中引发的凋亡和红系分化是完全可区分的过程,它们对胱天蛋白酶抑制表现出不同的敏感性。
Oncogene. 2007 Apr 12;26(17):2445-58. doi: 10.1038/sj.onc.1210034. Epub 2006 Oct 9.

引用本文的文献

1
Essential contribution of the JAK/STAT pathway to carcinogenesis, lytic infection of herpesviruses and pathogenesis of COVID‑19 (Review).JAK/STAT 通路在致癌作用、疱疹病毒的裂解感染和 COVID-19 发病机制中的重要作用(综述)。
Mol Med Rep. 2024 Mar;29(3). doi: 10.3892/mmr.2024.13163. Epub 2024 Jan 19.
2
Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models.将PKCδ抑制与传统酪氨酸激酶抑制剂(TKI)治疗相结合以靶向慢性粒细胞白血病(CML)模型。
Cancers (Basel). 2021 Apr 2;13(7):1693. doi: 10.3390/cancers13071693.
3
Implication and Regulation of AMPK during Physiological and Pathological Myeloid Differentiation.
AMPK 在生理和病理骨髓细胞分化过程中的作用和调控。
Int J Mol Sci. 2018 Sep 30;19(10):2991. doi: 10.3390/ijms19102991.
4
Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia.凋亡途径中的单核苷酸多态性与慢性髓性白血病对伊马替尼治疗的反应相关。
J Transl Med. 2016 Mar 24;14:82. doi: 10.1186/s12967-016-0837-5.
5
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia.抑制线粒体蛋白酶ClpP作为人类急性髓系白血病的治疗策略
Cancer Cell. 2015 Jun 8;27(6):864-76. doi: 10.1016/j.ccell.2015.05.004.
6
Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells.汉黄芩素可诱导伊马替尼耐药的K562细胞和原发性慢性粒细胞白血病细胞发生细胞周期阻滞和红系分化。
Oncotarget. 2014 Sep 30;5(18):8188-201. doi: 10.18632/oncotarget.2340.
7
Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia.十年使用的累积临床经验:伊马替尼作为慢性髓性白血病的一线治疗药物。
J Blood Med. 2012;3:139-50. doi: 10.2147/JBM.S29132. Epub 2012 Nov 16.
8
Knock-down of Kaiso induces proliferation and blocks granulocytic differentiation in blast crisis of chronic myeloid leukemia.Kaiso 敲低诱导慢性髓性白血病急变期细胞增殖并阻断粒细胞分化。
Cancer Cell Int. 2012 Jun 18;12(1):28. doi: 10.1186/1475-2867-12-28.
9
Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells.AXL在伊马替尼耐药慢性髓系白血病细胞中的过表达机制及功能
Oncotarget. 2011 Nov;2(11):874-85. doi: 10.18632/oncotarget.360.
10
Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death.阿昔洛韦通过依赖蛋白激酶 C 的自噬细胞死亡诱导来杀死慢性髓性白血病(CML)细胞。
PLoS One. 2009 Nov 18;4(11):e7889. doi: 10.1371/journal.pone.0007889.